<DOC>
	<DOCNO>NCT00093002</DOCNO>
	<brief_summary>The purpose study evaluate fulvestrant preliminary stage breast cancer treatment ass relationship dose , exposure , degree reduction tumor marker , efficacy postmenopausal woman estrogen receptor positive disease .</brief_summary>
	<brief_title>Fulvestrant ( FASLODEX™ ) Treatment Postmenopausal Women With Estrogen Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman define woman stop menstrual period Written inform consent participate trial Biopsy confirmation invasive breast cancer Evidence hormone sensitivity Willingness undergo biopsy Any previous treatment breast cancer Unwillingness stop take drug know affect sex hormonal status patient would inappropriate stop . Any severe concurrent condition would preclude surgery would jeopardize compliance study , e.g. , uncontrolled cardiac disease uncontrolled diabetes mellitus The presence one primary tumor History hypersensitivity castor oil History known bleeding disorder</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Early Breast Cancer</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>hormonal treatment</keyword>
	<keyword>newly diagnose breast cancer</keyword>
	<keyword>Estrogen Receptor Positive Breast Cancer</keyword>
	<keyword>treatment naïve</keyword>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>neoadjuvant setting</keyword>
	<keyword>invasive breast cancer</keyword>
</DOC>